Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Paul G Richardson,Philippe Moreau,Thierry Facon,Richard Labotka,Lotfi Benboubker,Robert M Rifkin,Kenshi Suzuki,Arun Kumar,Sophie Rigaudeau,Lionel Karlin,S Vincent Rajkumar,Nizar J Bahlis,Fritz Offner,Sagar Lonial,Darrell White,Xiaoquan Zhang,Christopher P Venner,Shaji Kumar,Sung‐Soo Yoon ,Éric Voog ,Philip Twumasi‐Ankrah ,Hirohiko Shibayama

doi:10.1182/blood-2021-148481

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Paul G Richardson, Philippe Moreau + Show 20 more

Open Access

https://doi.org/10.1182/blood-2021-148481

Copy DOI

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Full Text